C-(2-phenyl-cyclohexyl)-methylamine compounds for the treatment of anxiety disorders

Abstract

Pharmaceutical formulations of [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine and the metabolites thereof for treating anxiety, anxiety attacks and disorders as well as depression. Related methods of treating anxiety and anxiety attacks or depression are also provided, including methods of administering the active compounds as adjuvants to an antidepressant.

1 . A pharmaceutical formulation for treating anxiety disorders or depression comprising a pharmaceutically effective amount of a C-(2-phenyl-cyclohexyl)-methylamine compound selected from the group consisting of 
 3-(2-dimethylaminomethyl-cyclohexyl)-phenol,    (1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol,    [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine,    (1R,2R)-[2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine,    sulfuric acid mono-[3-(2-dimethylaminomethyl-cyclohexyl)-phenyl] ester,    sulfuric acid mono-(1R,2R)-[3-(2-dimethylaminomethyl-cyclohexyl)-phenyl] ester,    3-(2-methylaminomethyl-cyclohexyl)-phenol,    (1R,2R)-3-(2-methylaminomethyl-cyclohexyl)-phenol,    3-(2-dimethylaminomethyl-cyclohexyl)-phenol, N-oxide,    (1R, 2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol, N-oxide,    6-[3-(2-dimethylaminomethyl-cyclohexyl)-phenoxy]-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid,    6-[(1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenoxy]-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid,    4-(2-dimethylaminomethyl-cyclohexyl)-catechol,    (1R,2R)-4-(2-dimethylaminomethyl-cyclohexyl)-catechol,    3-(2-aminomethyl-cyclohexyl)-phenol,    (1R,2R)-3-(2-aminomethyl-cyclohexyl)-phenol,    C-[2-(3-methoxy-phenyl)-cyclohexyl]-methylamine,    (1R,2R)-C-[2-(3-methoxy-phenyl)-cyclohexyl]-methylamine,    [2-(3-methoxy-phenyl)-cyclohexylmethyl]-methylamine,    (1R,2R)-[2-(3-methoxy-phenyl)-cyclohexylmethyl]-methylamine,    [2-(3-methoxy-phenyl)-cyclohexylmethyl]-dimethylamine, N-oxide and    (1R,2R)-[2-(3-methoxy-phenyl)-cyclohexylmethyl]-dimethylamine, N-oxide,    or a physiologically acceptable salt thereof and a pharmaceutically acceptable carrier or adjuvant.    
   
   
       2 . The pharmaceutical formulation of  claim 1 , wherein said compound is present in the form of a free base.  
   
   
       3 . The pharmaceutical formulation of  claim 1 , wherein said compound is present in the form of a pure enantiomer or pure diastereoisomer.  
   
   
       4 . The pharmaceutical formulation of  claim 1 , wherein said compound is present in the form of a mixture of stereoisomers.  
   
   
       5 . The pharmaceutical formulation of  claim 1 , wherein said compound is present in the form of a racemic mixture.  
   
   
       6 . The pharmaceutical formulation of  claim 1 , wherein said compound is present in the form of a solvate.  
   
   
       7 . The pharmaceutical formulation of  claim 1 , wherein said compound is present in the form of a hydrate.  
   
   
       8 . The pharmaceutical formulation of  claim 1 , wherein said compound is present in the form of a 1R,2R enantiomer.  
   
   
       9 . A method for treating anxiety in a mammal, said method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a pharmaceutical formulation according to  claim 1 .  
   
   
       10 . A method according to  claim 9 , wherein the pharmaceutical formulation is administered at the first occurrence of an anxiety disorder.  
   
   
       11 . A method for treating anxiety or depression in a mammal, said method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a pharmaceutical formulation according to  claim 1 , said C-(2-phenyl-cyclohexyl)-methylamine compound being administered as an adjuvant to at least one antidepressant.